So, what does this mean for other biologics in PsO? According to the report, Humira has seen a 16% offset to share over the past year and Enbrel has given up more than 20%. Although future projections show this erosion curve to continue, actual offsets may come at a slower pace, particularly for Humira, which is extremely well-entrenched as a first line biologic, as well as the preferred biologic for certain PsO patient types. Furthermore, AbbVie dominates when it comes to perceptions about manufacturer support for patients, providers, and the dermatology community. <\/p>\n
Janssen's Stelara has carved out a solid position as the leading alternative mechanism biologic; however, the IL-17s are expected to catch up in the next six months, essentially flattening Stelara's growth. Indeed, among those expecting to increase their use of IL-17s, close to a third expect a corresponding decrease in the use of Stelara. <\/p>\n
Lastly, Celgene's Otezla has maintained a solid position as a psoriasis treatment and dermatologists do project gains in patients with mild and moderate disease. However, only half of the current Otezla patients are classified as \"well-managed\" compared to 71% of biologic-treated patients. Furthermore, dermatologists identified multiple barriers to increased use of Otezla, including market access challenges, issues with GI tolerability, and sustained efficacy. Until additional oral small molecule products enter the psoriasis market, Otezla has the corner on a market very much in demand by patients. <\/p>\n
The next wave of this study, RealTime Dynamix, will field in August and further drivers behind the evolution of this market will be explored next month in RealWorld Dynamix: Psoriasis, a large scale syndicated chart analysis of over 1,000 biologic\/apremilast treated patients that have recently switched brands. <\/p>\n
All company, brand or product names in this document are trademarks of their respective holders <\/p>\n
About Spherix Global Insights Spherix Global Insights is a business intelligence and market research company, specializing in renal, autoimmune, neurologic and rare disease markets. Our aim is to apply our commercial experience and unique relationships within core specialty markets to translate data into insight, enabling our clients to make smarter business decisions. <\/p>\n
For more information contact: Lynn Price, Immunology Franchise Head Email: info@spherixglobalinsights.com<\/a> http:\/\/www.spherixglobalinsights.com<\/a> <\/p>\n To view the original version on PR Newswire, visit:http:\/\/www.prnewswire.com\/news-releases\/novartis-cosentyx-and-eli-lillys-taltz-bring-disruption-to-the-psoriasis-market-as-il-17-share-increases-dramatically-300477250.html<\/a> <\/p>\n SOURCE Spherix Global Insights <\/p>\n